References
- Foran J M, Rohatiner A ZS, Coiffier B, Barbui T, Johnson S A, Hiddemann W, et al. Multicenter phase II study of fludarabine phosphate for patients with newly-diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinaemia, and mantle cell lymphoma. J Clin Oncol 1999; 17: 546–553
- Zinzani P L, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, et al. Randomized trial of fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000; 18: 773–779
- Decaudin D, Bosq J, Tertian G, Nedellec G, Bennaceur A, Venaut A, et al. Phase II trial of fludarabine monophosphate in patients with mantle cell lymphoma. J Clin Oncol 1998; 16: 579–583
- Cohen B J, Moskowitz C, Strauss D, Noy A, Hedrick E, Zelenetz A. Cyclophosphmaide/Fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymph 2001; 42: 1015–1022
- Rule S, Burton C, Waleski J, Jack A, Seymour J. A randomised phase II study of fludarabine/cyclophosphamide +/− rituximab in patients with untreated mantle cell lymphoma. Ann Oncol 2005; 16(Suppl 5)v95:198a
- Thomas D W, Owen R G, Johnson S AN, Hillmen P, Seymour J F, Wolf M M, et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymph 2005; 46: 549–552
- Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071
- Schulz H, Bohlius J F, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706–714
- Herold M, Haas A, Doerken B, Neser S, Al Ali K H, Neubauer A, et al. Immunochemotherapy (R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone – 50 months up date of the OSHO phase III study (OSHO#39). Ann Oncol 2008; 19(Suppl 4)iv85:010a
- Zelenetz A D, Persky D, Rice R D, Maragulia J, Weaver S A, Portlock C S, et al. Results of sequential chemotherapy followed by high dose therapy and autologous stem cell rescue for mantle cell lymphoma: role of rituximab and functional imaging. Ann Oncol 2008; 19(Suppl 4)iv85:013a
- Tam C S, Wolf M M, Januszewicz E H, Grigg A P, Prince H M, Westerman D, et al. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer 2004; 101: 2042–2049
- Kaplan L D, Lee J Y, Ambinder R F, Sparano J A, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS Malignancies Consortium Trial 010. Blood 2005; 106: 1538–1543
- Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984–1992
- Eve H E, Seymour J F, Rule S AJ. Impairment of peripheral blood stem cell mobilisation in patients with mantle cell lymphoma following primary treatment with fludarabine-based chemotherapy. Leuk Lymphoma, in press
- Vandenberghe E, Ruiz de Elvira C, Loberiza F R, Conde E, López-Guillermo A, Gisselbrecht C, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793–800